Tanya J. Major
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Tanya J. Major has a total of 178 co-authors. Here are the top co-authors by number of shared publications:
- Tony Raymond Merriman
Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL 35294, USA
14 shared publications - Lisa K. Stamp
Department of Medicine University of Otago Christchurch Christchurch New Zealand
9 shared publications - Nicola Dalbeth
Department of Medicine, Faculty of Medical and Health Sciences University of Auckland Auckland New Zealand
7 shared publications - Daniel E. Weeks
Department of Human Genetics, School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA
6 shared publications Nicola Dalbeth
Department of Medicine, University of Auckland, Auckland, New Zealand
6 shared publications- Rinki Murphy
Department of Medicine University of Auckland Auckland New Zealand
5 shared publications
Latest Publications
- Open Access
- 5 November 2024
- Published by Springer Nature in Nature Genetics
- Vol. 56 (11) , 2577
Publisher Correction: A genome-wide association analysis reveals new pathogenic pathways in gout
- 5 November 2024
- Published by Springer Nature in Nature Genetics
- Vol. 56 (11) , 2577
Open AccessPublisher Correction: A genome-wide association analysis reveals new pathogenic pathways in gout
- Top Cited Papers
- 15 October 2024
- Published by Springer Nature in Nature Genetics
- Vol. 56 (11) , 2392-2406
A genome-wide association analysis reveals new pathogenic pathways in gout
Gout is a chronic disease that is caused by an innate immune response to deposited monosodium urate crystals in the setting of hyperuricemia. Here, we provide insights into the molecular mechanism of the poorly understood inflammatory component of gout from a genome-wide association study (GWAS) of 2.6 million people, including 120,295 people with prevalent gout. We detected 377 loci and 410 genetically independent signals (149 previously unreported loci in urate and gout). An additional 65 loci with signals in urate (from a GWAS of 630,117 individuals) but not gout were identified. A prioritization scheme identified candidate genes in the inflammatory process of gout, including genes involved in epigenetic remodeling, cell osmolarity and regulation of NOD-like receptor protein 3 (NLRP3) inflammasome activity. Mendelian randomization analysis provided evidence for a causal role of clonal hematopoiesis of indeterminate potential in gout. Our study identifies candidate genes and molecular processes in the inflammatory pathogenesis of gout suitable for follow-up studies.
- 15 October 2024
- Published by Springer Nature in Nature Genetics
- Vol. 56 (11) , 2392-2406
Top Cited PapersA genome-wide association analysis reveals new pathogenic pathways in gout
Gout is a chronic disease that is caused by an innate immune response to deposited monosodium urate crystals in the setting of hyperuricemia. Here, we provide insights into the molecular mechanism of the poorly understood inflammatory component of gout from a genome-wide association study (GWAS) of 2.6 million people, including 120,295 people with prevalent gout. We detected 377 loci and 410 genetically independent signals (149 previously unreported loci in urate and gout). An additional 65 loci with signals in urate (from a GWAS of 630,117 individuals) but not gout were identified. A prioritization scheme identified candidate genes in the inflammatory process of gout, including genes involved in epigenetic remodeling, cell osmolarity and regulation of NOD-like receptor protein 3 (NLRP3) inflammasome activity. Mendelian randomization analysis provided evidence for a causal role of clonal hematopoiesis of indeterminate potential in gout. Our study identifies candidate genes and molecular processes in the inflammatory pathogenesis of gout suitable for follow-up studies.
- 2 March 2023
- Published by Springer Nature in Journal of Human Genetics
- Vol. 68 (7) , 463-468
Association of rs9939609 in FTO with BMI among Polynesian peoples living in Aotearoa New Zealand and other Pacific nations
The fat mass and obesity associated (FTO) locus consistently associates with higher body mass index (BMI) across diverse ancestral groups. However, previous small studies of people of Polynesian ancestries have failed to replicate the association. In this study, we used Bayesian meta-analysis to test rs9939609, the most replicated FTO variant, for association with BMI with a large sample (n = 6095) of Aotearoa New Zealanders of Polynesian (Māori and Pacific) ancestry and of Samoan people living in the Independent State of Samoa and in American Samoa. We did not observe statistically significant association within each separate Polynesian subgroup. Bayesian meta-analysis of the Aotearoa New Zealand Polynesian and Samoan samples resulted in a posterior mean effect size estimate of +0.21 kg/m2, with a 95% credible interval [+0.03 kg/m2, +0.39 kg/m2]. While the Bayes Factor (BF) of 0.77 weakly favors the null, the BF = 1.4 Bayesian support interval is [+0.04, +0.20]. These results suggest that rs9939609 in FTO may have a similar effect on mean BMI in people of Polynesian ancestries as previously observed in other ancestral groups.
- 2 March 2023
- Published by Springer Nature in Journal of Human Genetics
- Vol. 68 (7) , 463-468
Association of rs9939609 in FTO with BMI among Polynesian peoples living in Aotearoa New Zealand and other Pacific nations
The fat mass and obesity associated (FTO) locus consistently associates with higher body mass index (BMI) across diverse ancestral groups. However, previous small studies of people of Polynesian ancestries have failed to replicate the association. In this study, we used Bayesian meta-analysis to test rs9939609, the most replicated FTO variant, for association with BMI with a large sample (n = 6095) of Aotearoa New Zealanders of Polynesian (Māori and Pacific) ancestry and of Samoan people living in the Independent State of Samoa and in American Samoa. We did not observe statistically significant association within each separate Polynesian subgroup. Bayesian meta-analysis of the Aotearoa New Zealand Polynesian and Samoan samples resulted in a posterior mean effect size estimate of +0.21 kg/m2, with a 95% credible interval [+0.03 kg/m2, +0.39 kg/m2]. While the Bayes Factor (BF) of 0.77 weakly favors the null, the BF = 1.4 Bayesian support interval is [+0.04, +0.20]. These results suggest that rs9939609 in FTO may have a similar effect on mean BMI in people of Polynesian ancestries as previously observed in other ancestral groups.
- 9 November 2022
- Published by Wiley in Genetic Epidemiology
- Vol. 47 (1) , 105-118
Multivariate analysis of a missense variant in CREBRF reveals associations with measures of adiposity in people of Polynesian ancestries
The minor allele of rs373863828, a missense variant in CREB3 Regulatory Factor, is associated with several cardiometabolic phenotypes in Polynesian peoples. To better understand the variant, we tested the association of rs373863828 with a panel of correlated phenotypes (body mass index [BMI], weight, height, HDL cholesterol, triglycerides, and total cholesterol) using multivariate Bayesian association and network analyses in a Samoa cohort (n = 1632), Aotearoa New Zealand cohort (n = 1419), and combined cohort (n = 2976). An expanded set of phenotypes (adding estimated fat and fat‐free mass, abdominal circumference, hip circumference, and abdominal‐hip ratio) was tested in the Samoa cohort (n = 1496). In the Samoa cohort, we observed significant associations (log10 Bayes Factor [BF] ≥ 5.0) between rs373863828 and the overall phenotype panel (8.81), weight (8.30), and BMI (6.42). In the Aotearoa New Zealand cohort, we observed suggestive associations (1.5 < log10BF < 5) between rs373863828 and the overall phenotype panel (4.60), weight (3.27), and BMI (1.80). In the combined cohort, we observed concordant signals with larger log10BFs. In the Samoa‐specific expanded phenotype analyses, we also observed significant associations between rs373863828 and fat mass (5.65), abdominal circumference (5.34), and hip circumference (5.09). Bayesian networks provided evidence for a direct association of rs373863828 with weight and indirect associations with height and BMI.
- 9 November 2022
- Published by Wiley in Genetic Epidemiology
- Vol. 47 (1) , 105-118
Multivariate analysis of a missense variant in CREBRF reveals associations with measures of adiposity in people of Polynesian ancestries
The minor allele of rs373863828, a missense variant in CREB3 Regulatory Factor, is associated with several cardiometabolic phenotypes in Polynesian peoples. To better understand the variant, we tested the association of rs373863828 with a panel of correlated phenotypes (body mass index [BMI], weight, height, HDL cholesterol, triglycerides, and total cholesterol) using multivariate Bayesian association and network analyses in a Samoa cohort (n = 1632), Aotearoa New Zealand cohort (n = 1419), and combined cohort (n = 2976). An expanded set of phenotypes (adding estimated fat and fat‐free mass, abdominal circumference, hip circumference, and abdominal‐hip ratio) was tested in the Samoa cohort (n = 1496). In the Samoa cohort, we observed significant associations (log10 Bayes Factor [BF] ≥ 5.0) between rs373863828 and the overall phenotype panel (8.81), weight (8.30), and BMI (6.42). In the Aotearoa New Zealand cohort, we observed suggestive associations (1.5 < log10BF < 5) between rs373863828 and the overall phenotype panel (4.60), weight (3.27), and BMI (1.80). In the combined cohort, we observed concordant signals with larger log10BFs. In the Samoa‐specific expanded phenotype analyses, we also observed significant associations between rs373863828 and fat mass (5.65), abdominal circumference (5.34), and hip circumference (5.09). Bayesian networks provided evidence for a direct association of rs373863828 with weight and indirect associations with height and BMI.
- Open Access
Multivariate analysis of a missense variant in CREBRF reveals associations with measures of adiposity in people of Polynesian ancestries
Background: The Pacific-specific minor allele of rs373863828, a missense variant in CREB3 Regulatory Factor ( CREBRF ), is associated with several cardiometabolic phenotypes in Polynesian peoples, but the variant’s function remains poorly understood. To broaden our understanding of this variant, we used joint multivariate and network analyses to examine the relationships between rs373863828 and a panel of correlated anthropometric and lipid phenotypes. Methods: We tested the association of rs373863828 with a panel of phenotypes (body mass index [BMI], weight, height, HDL cholesterol, triglycerides, and total cholesterol) under a multivariate Bayesian association model in a cohort from Samoa (N = 1 632), a Māori and Pacific Island (Polynesian) cohort from Aotearoa New Zealand (N = 1 419), and the combined cohort (N = 2 976). An expanded set of phenotypes (adding estimated fat and fat-free mass, abdominal circumference, hip circumference, and abdominal-hip ratio) was also tested in the Samoa cohort (N = 1 496). Bayesian networks were learned to further understand the structure of the relationships. Results: In the Samoa cohort, significant associations (log 10 Bayes factor ≥5.0) were found between rs373863828 and the overall phenotype panel (7.97), weight (8.35) and BMI (6.39). In the Aotearoa New Zealand cohort, suggestive associations (log 10 Bayes factor between 1.5 and 5) were found between rs373863828 and the overall phenotype panel (3.64), weight (3.30), and BMI (1.79). In the combined cohort, concordant signals with stronger magnitudes were observed. In the expanded phenotype analyses among the Samoa cohort, significant associations were also observed between rs373863828 and fat mass (5.68), abdominal circumference (5.37), and hip circumference (5.15). Bayesian networks provided evidence for a direct association of rs373863828 with weight and indirect associations with height and BMI. Conclusions: When correlation structures were considered, multivariate Bayesian analyses provided additional evidence of rs373863828’s pleiotropic effects and highlighted a strong direct effect only on weight.
Open AccessMultivariate analysis of a missense variant in CREBRF reveals associations with measures of adiposity in people of Polynesian ancestries
Background: The Pacific-specific minor allele of rs373863828, a missense variant in CREB3 Regulatory Factor ( CREBRF ), is associated with several cardiometabolic phenotypes in Polynesian peoples, but the variant’s function remains poorly understood. To broaden our understanding of this variant, we used joint multivariate and network analyses to examine the relationships between rs373863828 and a panel of correlated anthropometric and lipid phenotypes. Methods: We tested the association of rs373863828 with a panel of phenotypes (body mass index [BMI], weight, height, HDL cholesterol, triglycerides, and total cholesterol) under a multivariate Bayesian association model in a cohort from Samoa (N = 1 632), a Māori and Pacific Island (Polynesian) cohort from Aotearoa New Zealand (N = 1 419), and the combined cohort (N = 2 976). An expanded set of phenotypes (adding estimated fat and fat-free mass, abdominal circumference, hip circumference, and abdominal-hip ratio) was also tested in the Samoa cohort (N = 1 496). Bayesian networks were learned to further understand the structure of the relationships. Results: In the Samoa cohort, significant associations (log 10 Bayes factor ≥5.0) were found between rs373863828 and the overall phenotype panel (7.97), weight (8.35) and BMI (6.39). In the Aotearoa New Zealand cohort, suggestive associations (log 10 Bayes factor between 1.5 and 5) were found between rs373863828 and the overall phenotype panel (3.64), weight (3.30), and BMI (1.79). In the combined cohort, concordant signals with stronger magnitudes were observed. In the expanded phenotype analyses among the Samoa cohort, significant associations were also observed between rs373863828 and fat mass (5.68), abdominal circumference (5.37), and hip circumference (5.15). Bayesian networks provided evidence for a direct association of rs373863828 with weight and indirect associations with height and BMI. Conclusions: When correlation structures were considered, multivariate Bayesian analyses provided additional evidence of rs373863828’s pleiotropic effects and highlighted a strong direct effect only on weight.
- Open Access
- 22 April 2022
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 31 (21) , 3757-3768
A Polynesian-specific copy number variant encompassing the MICA gene associates with gout
Gout is of particularly high prevalence in the Māori and Pacific (Polynesian) populations of Aotearoa New Zealand (NZ). Here, we investigated the contribution of common population-specific copy number variation (CNV) to gout in the Aotearoa NZ Polynesian population. Microarray-generated genome-wide genotype data from Aotearoa NZ Polynesian individuals with (n = 1196) and without (n = 1249) gout were analyzed. Comparator population groups were 552 individuals of European ancestry and 1962 of Han Chinese ancestry. Levels of circulating major histocompatibility complex (MHC) class I polypeptide-related sequence A (MICA) were measured by enzyme-linked immunosorbent assay. Fifty-four CNV regions (CNVRs) appearing in at least 10 individuals were detected, of which seven common (>2%) CNVRs were specific to or amplified in Polynesian people. A burden test of these seven revealed associations of insertion/deletion with gout (odds ratio (OR) 95% confidence interval [CI] = 1.80 [1.01; 3.22], P = 0.046). Individually testing of the seven CNVRs for association with gout revealed nominal association of CNVR1 with gout in Western Polynesian (Chr6: 31.36–31.45 Mb, OR = 1.72 [1.03; 2.92], P = 0.04), CNVR6 in the meta-analyzed Polynesian sample sets (Chr1: 196.75–196.92 Mb, OR = 1.86 [1.16; 3.00], P = 0.01) and CNVR9 in Western Polynesian (Chr1: 189.35–189.54 Mb, OR = 2.75 [1.15; 7.13], P = 0.03). Analysis of European gout genetic association data demonstrated a signal of association at the CNVR1 locus that was an expression quantitative trait locus for MICA. The most common CNVR (CNVR1) includes deletion of the MICA gene, encoding an immunomodulatory protein. Expression of MICA was reduced in the serum of individuals with the deletion. In summary, we provide evidence for the association of CNVR1 containing MICA with gout in Polynesian people, implicating class I MHC-mediated antigen presentation in gout.
- 22 April 2022
- Published by Oxford University Press (OUP) in Human Molecular Genetics
- Vol. 31 (21) , 3757-3768
Open AccessA Polynesian-specific copy number variant encompassing the MICA gene associates with gout
Gout is of particularly high prevalence in the Māori and Pacific (Polynesian) populations of Aotearoa New Zealand (NZ). Here, we investigated the contribution of common population-specific copy number variation (CNV) to gout in the Aotearoa NZ Polynesian population. Microarray-generated genome-wide genotype data from Aotearoa NZ Polynesian individuals with (n = 1196) and without (n = 1249) gout were analyzed. Comparator population groups were 552 individuals of European ancestry and 1962 of Han Chinese ancestry. Levels of circulating major histocompatibility complex (MHC) class I polypeptide-related sequence A (MICA) were measured by enzyme-linked immunosorbent assay. Fifty-four CNV regions (CNVRs) appearing in at least 10 individuals were detected, of which seven common (>2%) CNVRs were specific to or amplified in Polynesian people. A burden test of these seven revealed associations of insertion/deletion with gout (odds ratio (OR) 95% confidence interval [CI] = 1.80 [1.01; 3.22], P = 0.046). Individually testing of the seven CNVRs for association with gout revealed nominal association of CNVR1 with gout in Western Polynesian (Chr6: 31.36–31.45 Mb, OR = 1.72 [1.03; 2.92], P = 0.04), CNVR6 in the meta-analyzed Polynesian sample sets (Chr1: 196.75–196.92 Mb, OR = 1.86 [1.16; 3.00], P = 0.01) and CNVR9 in Western Polynesian (Chr1: 189.35–189.54 Mb, OR = 2.75 [1.15; 7.13], P = 0.03). Analysis of European gout genetic association data demonstrated a signal of association at the CNVR1 locus that was an expression quantitative trait locus for MICA. The most common CNVR (CNVR1) includes deletion of the MICA gene, encoding an immunomodulatory protein. Expression of MICA was reduced in the serum of individuals with the deletion. In summary, we provide evidence for the association of CNVR1 containing MICA with gout in Polynesian people, implicating class I MHC-mediated antigen presentation in gout.
- Open Access
CREBRF missense variant rs373863828 has both direct and indirect effects on type 2 diabetes and fasting glucose in Polynesians living in Samoa and Aotearoa New Zealand
Objective: The minor allele of rs373863828 in CREBRF is associated with higher BMI, lower fasting glucose, and lower odds of type 2 diabetes. We examined the associations between BMI and rs373863828 on type 2 diabetes and fasting glucose with a large sample of adult Polynesians from Samoa, American Samoa and Aotearoa New Zealand and estimated direct and indirect (via BMI) effects of rs373863828 on type 2 diabetes and fasting glucose. Research Design and Methods: We regressed type 2 diabetes and fasting glucose on BMI and rs373863828 stratified by obesity, regressed type 2 diabetes and fasting glucose on BMI stratified by rs373863828 genotype, and assessed the effects of rs373863828 on type 2 diabetes and fasting glucose with path analysis. Results: Association of BMI with fasting glucose was greater in those without obesity than in those with obesity. We did not observe evidence of differences by genotype. In the path analysis, the minor allele has direct negative and indirect positive effects on type 2 diabetes risk and fasting glucose, with the indirect effect mediated through a direct positive effect on BMI. Conclusions: There may be a stronger effect of BMI on fasting glucose in Polynesians without obesity than in those with obesity. Carrying the rs373863828 minor allele does not decouple higher BMI from odds of type 2 diabetes. Given the current cost of genotyping compared to the accessibility of measuring BMI, including rs373863828 as a clinical predictor of type 2 diabetes may not be indicated.
Open AccessCREBRF missense variant rs373863828 has both direct and indirect effects on type 2 diabetes and fasting glucose in Polynesians living in Samoa and Aotearoa New Zealand
Objective: The minor allele of rs373863828 in CREBRF is associated with higher BMI, lower fasting glucose, and lower odds of type 2 diabetes. We examined the associations between BMI and rs373863828 on type 2 diabetes and fasting glucose with a large sample of adult Polynesians from Samoa, American Samoa and Aotearoa New Zealand and estimated direct and indirect (via BMI) effects of rs373863828 on type 2 diabetes and fasting glucose. Research Design and Methods: We regressed type 2 diabetes and fasting glucose on BMI and rs373863828 stratified by obesity, regressed type 2 diabetes and fasting glucose on BMI stratified by rs373863828 genotype, and assessed the effects of rs373863828 on type 2 diabetes and fasting glucose with path analysis. Results: Association of BMI with fasting glucose was greater in those without obesity than in those with obesity. We did not observe evidence of differences by genotype. In the path analysis, the minor allele has direct negative and indirect positive effects on type 2 diabetes risk and fasting glucose, with the indirect effect mediated through a direct positive effect on BMI. Conclusions: There may be a stronger effect of BMI on fasting glucose in Polynesians without obesity than in those with obesity. Carrying the rs373863828 minor allele does not decouple higher BMI from odds of type 2 diabetes. Given the current cost of genotyping compared to the accessibility of measuring BMI, including rs373863828 as a clinical predictor of type 2 diabetes may not be indicated.
- Open Access
- 7 January 2020
- Published by Cold Spring Harbor Laboratory in bioRxiv
Pleiotropic effect of ABCG2 in gout: involvement in serum urate levels and progression from hyperuricemia to gout
Background: The ABCG2 Q141K (rs2231142) andrs10011796variants associate with hyperuricaemia (HU). The effect size ofABCG2 rs2231142on urate is ∼60% that ofSLC2A9, yet the effect size on gout is greater. We tested the hypothesis that ABCG2 plays a role in the progression from HU to gout by testing for association ofABCG2 rs2231142andrs10011796with gout using HU controls.Methods: We analysed 1,699 European gout cases and 14,350 normourciemic (NU) and HU controls, and 912 New Zealand (NZ) Polynesian (divided into Eastern and Western Polynesian) gout cases and 696 controls. Association testing was performed using logistic and linear regression with multivariate adjusting for confounding variables.Results: In Europeans and Polynesians, theABCG2141K (T) allele was associated with gout using HU controls (OR=1.85,P=3.8E-21and ORmeta=1.85,P=1.3E-03, respectively). There was evidence for an effect of 141K in determining HU in European (OR=1.56,P=1.7E-18) but not in Polynesian (ORmeta=1.49,P=0.057). ForSLC2A9 rs11942223, the T allele associated with gout in the presence of HU in European (OR=1.37,P=4.7E-06), however significantly weaker thanABCG2 rs2231142141K (PHet=0.0023). In Western Polynesian and European, there was epistatic interaction betweenABCG2 rs2231142and the genetically-independentrs10011796. Combining the presence of the 141K allele with thers10011796CC-genotype increased gout risk, in the presence of HU, 21.5-fold in Western Polynesian (P=0.009) and 2.6-fold in European (P=9.9E-06). The 141K allele positively associated with flare frequency in Polynesian (Pmeta=2.5E-03).Conclusion: These data are consistent with a role forABCG2141K in gout in the presence of established HU.
- 7 January 2020
- Published by Cold Spring Harbor Laboratory in bioRxiv
Open AccessPleiotropic effect of ABCG2 in gout: involvement in serum urate levels and progression from hyperuricemia to gout
Background: The ABCG2 Q141K (rs2231142) andrs10011796variants associate with hyperuricaemia (HU). The effect size ofABCG2 rs2231142on urate is ∼60% that ofSLC2A9, yet the effect size on gout is greater. We tested the hypothesis that ABCG2 plays a role in the progression from HU to gout by testing for association ofABCG2 rs2231142andrs10011796with gout using HU controls.Methods: We analysed 1,699 European gout cases and 14,350 normourciemic (NU) and HU controls, and 912 New Zealand (NZ) Polynesian (divided into Eastern and Western Polynesian) gout cases and 696 controls. Association testing was performed using logistic and linear regression with multivariate adjusting for confounding variables.Results: In Europeans and Polynesians, theABCG2141K (T) allele was associated with gout using HU controls (OR=1.85,P=3.8E-21and ORmeta=1.85,P=1.3E-03, respectively). There was evidence for an effect of 141K in determining HU in European (OR=1.56,P=1.7E-18) but not in Polynesian (ORmeta=1.49,P=0.057). ForSLC2A9 rs11942223, the T allele associated with gout in the presence of HU in European (OR=1.37,P=4.7E-06), however significantly weaker thanABCG2 rs2231142141K (PHet=0.0023). In Western Polynesian and European, there was epistatic interaction betweenABCG2 rs2231142and the genetically-independentrs10011796. Combining the presence of the 141K allele with thers10011796CC-genotype increased gout risk, in the presence of HU, 21.5-fold in Western Polynesian (P=0.009) and 2.6-fold in European (P=9.9E-06). The 141K allele positively associated with flare frequency in Polynesian (Pmeta=2.5E-03).Conclusion: These data are consistent with a role forABCG2141K in gout in the presence of established HU.
- Top Cited PapersOpen Access
Evaluation of the diet wide contribution to serum urate levels: meta-analysis of population based cohorts
Objective: To systematically test dietary components for association with serum urate levels and to evaluate the relative contributions of estimates of diet pattern and inherited genetic variants to population variance in serum urate levels. Design: Meta-analysis of cross sectional data from the United States. Data sources: Five cohort studies. Review methods: 16 760 individuals of European ancestry (8414 men and 8346 women) from the US were included in analyses. Eligible individuals were aged over 18, without kidney disease or gout, and not taking urate lowering or diuretic drugs. All participants had serum urate measurements, dietary survey data, information on potential confounders (sex, age, body mass index, average daily calorie intake, years of education, exercise levels, smoking status, and menopausal status), and genome wide genotypes. The main outcome measures were average serum urate levels and variance in serum urate levels. β values (95% confidence intervals) and Bonferroni corrected P values from multivariable linear regression analyses, along with regression partial R 2 values, were used to quantitate associations. Results: Seven foods were associated with raised serum urate levels (beer, liquor, wine, potato, poultry, soft drinks, and meat (beef, pork, or lamb)) and eight foods were associated with reduced serum urate levels (eggs, peanuts, cold cereal, skim milk, cheese, brown bread, margarine, and non-citrus fruits) in the male, female, or full cohorts. Three diet scores, constructed on the basis of healthy diet guidelines, were inversely associated with serum urate levels and a fourth, data driven diet pattern positively associated with raised serum urate levels, but each explained ≤0.3% of variance in serum urate. In comparison, 23.9% of variance in serum urate levels was explained by common, genome wide single nucleotide variation. Conclusion: In contrast with genetic contributions, diet explains very little variation in serum urate levels in the general population.
Top Cited PapersOpen AccessEvaluation of the diet wide contribution to serum urate levels: meta-analysis of population based cohorts
Objective: To systematically test dietary components for association with serum urate levels and to evaluate the relative contributions of estimates of diet pattern and inherited genetic variants to population variance in serum urate levels. Design: Meta-analysis of cross sectional data from the United States. Data sources: Five cohort studies. Review methods: 16 760 individuals of European ancestry (8414 men and 8346 women) from the US were included in analyses. Eligible individuals were aged over 18, without kidney disease or gout, and not taking urate lowering or diuretic drugs. All participants had serum urate measurements, dietary survey data, information on potential confounders (sex, age, body mass index, average daily calorie intake, years of education, exercise levels, smoking status, and menopausal status), and genome wide genotypes. The main outcome measures were average serum urate levels and variance in serum urate levels. β values (95% confidence intervals) and Bonferroni corrected P values from multivariable linear regression analyses, along with regression partial R 2 values, were used to quantitate associations. Results: Seven foods were associated with raised serum urate levels (beer, liquor, wine, potato, poultry, soft drinks, and meat (beef, pork, or lamb)) and eight foods were associated with reduced serum urate levels (eggs, peanuts, cold cereal, skim milk, cheese, brown bread, margarine, and non-citrus fruits) in the male, female, or full cohorts. Three diet scores, constructed on the basis of healthy diet guidelines, were inversely associated with serum urate levels and a fourth, data driven diet pattern positively associated with raised serum urate levels, but each explained ≤0.3% of variance in serum urate. In comparison, 23.9% of variance in serum urate levels was explained by common, genome wide single nucleotide variation. Conclusion: In contrast with genetic contributions, diet explains very little variation in serum urate levels in the general population.
- Open Access
- 15 August 2018
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 20 (1) , 179
The relationship between ferritin and urate levels and risk of gout
Ferritin positively associates with serum urate and an interventional study suggests that iron has a role in triggering gout flares. The objective of this study was to further explore the relationship between iron/ferritin and urate/gout. European (100 cases, 60 controls) and Polynesian (100 cases, 60 controls) New Zealand (NZ) males and 189 US male cases and 60 male controls participated. The 10,727 participants without gout were from the Jackson Heart (JHS; African American = 1260) and NHANES III (European = 5112; African American = 4355) studies. Regression analyses were adjusted for age, sex, body mass index and C-reactive protein. To test for a causal relationship between ferritin and urate, bidirectional two-sample Mendelian randomization analysis was performed. Serum ferritin positively associated with gout in NZ Polynesian (OR (per 10 ng ml− 1 increase) = 1.03, p = 1.8E–03) and US (OR = 1.11, p = 7.4E–06) data sets but not in NZ European (OR = 1.00, p = 0.84) data sets. Ferritin positively associated with urate in NZ Polynesian (β (mg dl− 1) = 0.014, p = 2.5E–04), JHS (β = 0.009, p = 3.2E–05) and NHANES III (European β = 0.007, p = 5.1E–11; African American β = 0.011, p = 2.1E–16) data sets but not in NZ European (β = 0.009, p = 0.31) or US (β = 0.041, p = 0.15) gout data sets. Ferritin positively associated with the frequency of gout flares in two of the gout data sets. By Mendelian randomization analysis a one standard deviation unit increase in iron and ferritin was, respectively, associated with 0.11 (p = 8E–04) and 0.19 mg dl− 1 (p = 2E–04) increases in serum urate. There was no evidence for a causal effect of urate on iron/ferritin. These data replicate the association of ferritin with serum urate. Increased ferritin levels associated with gout and flare frequency. There was evidence of a causal effect of iron and ferritin on urate.
- 15 August 2018
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 20 (1) , 179
Open AccessThe relationship between ferritin and urate levels and risk of gout
Ferritin positively associates with serum urate and an interventional study suggests that iron has a role in triggering gout flares. The objective of this study was to further explore the relationship between iron/ferritin and urate/gout. European (100 cases, 60 controls) and Polynesian (100 cases, 60 controls) New Zealand (NZ) males and 189 US male cases and 60 male controls participated. The 10,727 participants without gout were from the Jackson Heart (JHS; African American = 1260) and NHANES III (European = 5112; African American = 4355) studies. Regression analyses were adjusted for age, sex, body mass index and C-reactive protein. To test for a causal relationship between ferritin and urate, bidirectional two-sample Mendelian randomization analysis was performed. Serum ferritin positively associated with gout in NZ Polynesian (OR (per 10 ng ml− 1 increase) = 1.03, p = 1.8E–03) and US (OR = 1.11, p = 7.4E–06) data sets but not in NZ European (OR = 1.00, p = 0.84) data sets. Ferritin positively associated with urate in NZ Polynesian (β (mg dl− 1) = 0.014, p = 2.5E–04), JHS (β = 0.009, p = 3.2E–05) and NHANES III (European β = 0.007, p = 5.1E–11; African American β = 0.011, p = 2.1E–16) data sets but not in NZ European (β = 0.009, p = 0.31) or US (β = 0.041, p = 0.15) gout data sets. Ferritin positively associated with the frequency of gout flares in two of the gout data sets. By Mendelian randomization analysis a one standard deviation unit increase in iron and ferritin was, respectively, associated with 0.11 (p = 8E–04) and 0.19 mg dl− 1 (p = 2E–04) increases in serum urate. There was no evidence for a causal effect of urate on iron/ferritin. These data replicate the association of ferritin with serum urate. Increased ferritin levels associated with gout and flare frequency. There was evidence of a causal effect of iron and ferritin on urate.